Form 8-K - Current report:
SEC Accession No. 0001437749-25-021153
Filing Date
2025-06-24
Accepted
2025-06-24 16:06:18
Documents
14
Period of Report
2025-06-19
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20250620_8k.htm   iXBRL 8-K 25316
2 EXHIBIT 3.1 ex_833086.htm EX-3.1 154423
  Complete submission text file 0001437749-25-021153.txt   346419

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20250619.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20250619_def.xml EX-101.DEF 11804
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20250619_lab.xml EX-101.LAB 15848
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20250619_pre.xml EX-101.PRE 12019
16 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20250620_8k_htm.xml XML 2964
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 251069010
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)